nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—Nucleic Acid Synthesis Inhibitors—Gemcitabine—urinary bladder cancer	0.18	0.515	CiPCiCtD
Capecitabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—urinary bladder cancer	0.169	0.485	CiPCiCtD
Capecitabine—TYMP—urinary bladder cancer	0.124	0.68	CbGaD
Capecitabine—prostate cancer—urinary bladder cancer	0.123	0.579	CtDrD
Capecitabine—kidney cancer—urinary bladder cancer	0.0895	0.421	CtDrD
Capecitabine—TYMS—urinary bladder cancer	0.0582	0.32	CbGaD
Capecitabine—DPYD—Fluorouracil—urinary bladder cancer	0.0497	0.277	CbGbCtD
Capecitabine—CDA—Gemcitabine—urinary bladder cancer	0.0462	0.257	CbGbCtD
Capecitabine—TYMP—Fluorouracil—urinary bladder cancer	0.033	0.184	CbGbCtD
Capecitabine—TYMS—Gemcitabine—urinary bladder cancer	0.0206	0.115	CbGbCtD
Capecitabine—TYMS—Fluorouracil—urinary bladder cancer	0.0176	0.098	CbGbCtD
Capecitabine—TYMS—Methotrexate—urinary bladder cancer	0.0097	0.0541	CbGbCtD
Capecitabine—CYP2C9—Fluorouracil—urinary bladder cancer	0.00139	0.00776	CbGbCtD
Capecitabine—CYP2C9—Cisplatin—urinary bladder cancer	0.00118	0.00659	CbGbCtD
Capecitabine—DPYD—prostate gland—urinary bladder cancer	0.00104	0.112	CbGeAlD
Capecitabine—CDA—prostate gland—urinary bladder cancer	0.001	0.108	CbGeAlD
Capecitabine—CYP2C9—urine—urinary bladder cancer	0.00063	0.0679	CbGeAlD
Capecitabine—TYMP—prostate gland—urinary bladder cancer	0.000604	0.0651	CbGeAlD
Capecitabine—CES1—prostate gland—urinary bladder cancer	0.000521	0.0562	CbGeAlD
Capecitabine—TYMS—prostate gland—urinary bladder cancer	0.000518	0.0559	CbGeAlD
Capecitabine—TYMP—seminal vesicle—urinary bladder cancer	0.000511	0.0551	CbGeAlD
Capecitabine—CDA—vagina—urinary bladder cancer	0.000495	0.0534	CbGeAlD
Capecitabine—TYMP—smooth muscle tissue—urinary bladder cancer	0.000427	0.0461	CbGeAlD
Capecitabine—TYMP—urethra—urinary bladder cancer	0.000404	0.0436	CbGeAlD
Capecitabine—TYMS—smooth muscle tissue—urinary bladder cancer	0.000367	0.0396	CbGeAlD
Capecitabine—DPYD—lymph node—urinary bladder cancer	0.000333	0.0359	CbGeAlD
Capecitabine—TYMP—female reproductive system—urinary bladder cancer	0.00033	0.0355	CbGeAlD
Capecitabine—CDA—lymph node—urinary bladder cancer	0.00032	0.0345	CbGeAlD
Capecitabine—TYMS—Podofilox—Etoposide—urinary bladder cancer	0.000301	0.713	CbGdCrCtD
Capecitabine—TYMP—vagina—urinary bladder cancer	0.000298	0.0321	CbGeAlD
Capecitabine—CES1—female reproductive system—urinary bladder cancer	0.000284	0.0307	CbGeAlD
Capecitabine—TYMS—female reproductive system—urinary bladder cancer	0.000283	0.0305	CbGeAlD
Capecitabine—TYMS—vagina—urinary bladder cancer	0.000256	0.0276	CbGeAlD
Capecitabine—TYMP—lymph node—urinary bladder cancer	0.000193	0.0208	CbGeAlD
Capecitabine—CES1—lymph node—urinary bladder cancer	0.000166	0.0179	CbGeAlD
Capecitabine—TYMS—lymph node—urinary bladder cancer	0.000165	0.0178	CbGeAlD
Capecitabine—CYP2C9—female reproductive system—urinary bladder cancer	0.000123	0.0133	CbGeAlD
Capecitabine—TYMS—Azacitidine—Gemcitabine—urinary bladder cancer	0.000121	0.287	CbGdCrCtD
Capecitabine—CES1—NRF2 pathway—GSTP1—urinary bladder cancer	5.3e-05	0.00203	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	5.27e-05	0.00201	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTO2—urinary bladder cancer	5.14e-05	0.00196	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NAT1—urinary bladder cancer	5.14e-05	0.00196	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—CDKN2A—urinary bladder cancer	5.11e-05	0.00195	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—PLAU—urinary bladder cancer	4.91e-05	0.00188	CbGpPWpGaD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	4.89e-05	0.00187	CbGpPWpGaD
Capecitabine—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	4.87e-05	0.00186	CbGpPWpGaD
Capecitabine—CES1—NRF2 pathway—GSTM1—urinary bladder cancer	4.87e-05	0.00186	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSTZ1—urinary bladder cancer	4.83e-05	0.00185	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—UGT2B7—urinary bladder cancer	4.7e-05	0.0018	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—ATM—urinary bladder cancer	4.66e-05	0.00178	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSTO2—urinary bladder cancer	4.58e-05	0.00175	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NAT1—urinary bladder cancer	4.58e-05	0.00175	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	4.41e-05	0.00169	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—CCNE1—urinary bladder cancer	4.4e-05	0.00168	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	4.38e-05	0.00168	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CYP4B1—urinary bladder cancer	4.23e-05	0.00162	CbGpPWpGaD
Capecitabine—CDA—Metabolism—UGT2B7—urinary bladder cancer	4.19e-05	0.0016	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—CDKN1A—urinary bladder cancer	4.18e-05	0.0016	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—CREBBP—urinary bladder cancer	4.05e-05	0.00155	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—RB1—urinary bladder cancer	4.03e-05	0.00154	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	4.03e-05	0.00154	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—SLC19A1—urinary bladder cancer	4e-05	0.00153	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—EP300—urinary bladder cancer	3.98e-05	0.00152	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PRSS3—urinary bladder cancer	3.89e-05	0.00149	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTZ1—urinary bladder cancer	3.86e-05	0.00148	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CYP4B1—urinary bladder cancer	3.77e-05	0.00144	CbGpPWpGaD
Capecitabine—TYMS—Fluoropyrimidine Activity—TP53—urinary bladder cancer	3.73e-05	0.00142	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	3.72e-05	0.00142	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	3.71e-05	0.00142	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	3.69e-05	0.00141	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTO2—urinary bladder cancer	3.66e-05	0.0014	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—NAT1—urinary bladder cancer	3.66e-05	0.0014	CbGpPWpGaD
Capecitabine—CDA—Metabolism—SLC19A1—urinary bladder cancer	3.56e-05	0.00136	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—CDKN2A—urinary bladder cancer	3.55e-05	0.00136	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	3.53e-05	0.00135	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	3.51e-05	0.00134	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PRSS3—urinary bladder cancer	3.47e-05	0.00133	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—MYC—urinary bladder cancer	3.46e-05	0.00132	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—UGT2B7—urinary bladder cancer	3.35e-05	0.00128	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	3.33e-05	0.00127	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—ESPL1—urinary bladder cancer	3.3e-05	0.00126	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	3.28e-05	0.00126	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	3.16e-05	0.00121	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	3.16e-05	0.00121	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	3.11e-05	0.00119	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—TYMP—urinary bladder cancer	3.11e-05	0.00119	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—CYP4B1—urinary bladder cancer	3.01e-05	0.00115	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—RB1—urinary bladder cancer	2.93e-05	0.00112	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—CDKN1A—urinary bladder cancer	2.9e-05	0.00111	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	2.89e-05	0.0011	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	2.85e-05	0.00109	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—SLC19A1—urinary bladder cancer	2.85e-05	0.00109	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	2.84e-05	0.00108	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NAT2—urinary bladder cancer	2.82e-05	0.00108	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	2.81e-05	0.00107	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	2.8e-05	0.00107	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	2.8e-05	0.00107	CbGpPWpGaD
Capecitabine—CDA—Metabolism—TYMP—urinary bladder cancer	2.77e-05	0.00106	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PRSS3—urinary bladder cancer	2.77e-05	0.00106	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—EP300—urinary bladder cancer	2.76e-05	0.00105	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—NCOR1—urinary bladder cancer	2.62e-05	0.001	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	2.6e-05	0.000995	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	2.6e-05	0.000993	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	2.56e-05	0.00098	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	2.52e-05	0.000963	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NAT2—urinary bladder cancer	2.51e-05	0.000959	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—STAG2—urinary bladder cancer	2.5e-05	0.000957	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—LIG1—urinary bladder cancer	2.5e-05	0.000957	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	2.47e-05	0.000943	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.44e-05	0.000934	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—RRM2—urinary bladder cancer	2.43e-05	0.000929	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—MYC—urinary bladder cancer	2.4e-05	0.000919	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—FAS—urinary bladder cancer	2.35e-05	0.000896	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	2.31e-05	0.000881	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—ENO2—urinary bladder cancer	2.25e-05	0.00086	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—HPGDS—urinary bladder cancer	2.25e-05	0.00086	CbGpPWpGaD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	2.24e-05	0.000856	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	2.2e-05	0.00084	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTT1—urinary bladder cancer	2.18e-05	0.000834	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	2.17e-05	0.000829	CbGpPWpGaD
Capecitabine—CDA—Metabolism—RRM2—urinary bladder cancer	2.17e-05	0.000828	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.16e-05	0.000825	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.15e-05	0.000822	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.14e-05	0.000818	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—CDKN1A—urinary bladder cancer	2.1e-05	0.000804	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	2.09e-05	0.000798	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—CDK4—urinary bladder cancer	2.06e-05	0.000789	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—RRM2—urinary bladder cancer	2.06e-05	0.000788	CbGpPWpGaD
Capecitabine—CDA—Metabolism—HPGDS—urinary bladder cancer	2.01e-05	0.000767	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ENO2—urinary bladder cancer	2.01e-05	0.000767	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—NAT2—urinary bladder cancer	2.01e-05	0.000767	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTZ1—urinary bladder cancer	1.98e-05	0.000755	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	1.96e-05	0.000749	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSTT1—urinary bladder cancer	1.95e-05	0.000744	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.88e-05	0.000717	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—PPARG—urinary bladder cancer	1.87e-05	0.000717	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTO2—urinary bladder cancer	1.87e-05	0.000716	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NAT1—urinary bladder cancer	1.87e-05	0.000716	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.85e-05	0.000708	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	1.83e-05	0.0007	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NQO1—urinary bladder cancer	1.81e-05	0.000693	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	1.77e-05	0.000677	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—SMC1A—urinary bladder cancer	1.75e-05	0.00067	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—MYC—urinary bladder cancer	1.74e-05	0.000667	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—RRM2—urinary bladder cancer	1.73e-05	0.000662	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	1.73e-05	0.000661	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	1.72e-05	0.000656	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—UGT2B7—urinary bladder cancer	1.71e-05	0.000655	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	1.71e-05	0.000652	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NQO1—urinary bladder cancer	1.62e-05	0.000618	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ENO2—urinary bladder cancer	1.6e-05	0.000613	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—HPGDS—urinary bladder cancer	1.6e-05	0.000613	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.57e-05	0.0006	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTT1—urinary bladder cancer	1.56e-05	0.000594	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CYP4B1—urinary bladder cancer	1.54e-05	0.000589	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.54e-05	0.000587	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTP1—urinary bladder cancer	1.51e-05	0.000578	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	1.47e-05	0.000562	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—SLC19A1—urinary bladder cancer	1.46e-05	0.000557	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PRSS3—urinary bladder cancer	1.42e-05	0.000542	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—TYMS—urinary bladder cancer	1.41e-05	0.000538	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NCOR1—urinary bladder cancer	1.39e-05	0.000531	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTM1—urinary bladder cancer	1.39e-05	0.000531	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.39e-05	0.000531	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	1.38e-05	0.000528	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	1.36e-05	0.000519	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSTP1—urinary bladder cancer	1.35e-05	0.000515	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.34e-05	0.000513	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	1.34e-05	0.000513	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.34e-05	0.000512	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GPX1—urinary bladder cancer	1.33e-05	0.000509	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—ERCC2—urinary bladder cancer	1.31e-05	0.0005	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	1.29e-05	0.000495	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—NQO1—urinary bladder cancer	1.29e-05	0.000494	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—PTEN—urinary bladder cancer	1.29e-05	0.000492	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.28e-05	0.000488	CbGpPWpGaD
Capecitabine—CDA—Metabolism—TYMS—urinary bladder cancer	1.25e-05	0.000479	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.24e-05	0.000475	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GSTM1—urinary bladder cancer	1.24e-05	0.000474	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NCOR1—urinary bladder cancer	1.24e-05	0.000474	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—MTHFR—urinary bladder cancer	1.23e-05	0.00047	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—EP300—urinary bladder cancer	1.23e-05	0.000469	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CCNE1—urinary bladder cancer	1.22e-05	0.000464	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GPX1—urinary bladder cancer	1.19e-05	0.000454	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ERCC2—urinary bladder cancer	1.17e-05	0.000445	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—TYMP—urinary bladder cancer	1.13e-05	0.000434	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.11e-05	0.000426	CbGpPWpGaD
Capecitabine—Tinnitus—Methotrexate—urinary bladder cancer	1.11e-05	0.000268	CcSEcCtD
Capecitabine—Hypoaesthesia—Epirubicin—urinary bladder cancer	1.11e-05	0.000267	CcSEcCtD
Capecitabine—Asthenia—Cisplatin—urinary bladder cancer	1.11e-05	0.000267	CcSEcCtD
Capecitabine—Pharyngitis—Epirubicin—urinary bladder cancer	1.11e-05	0.000267	CcSEcCtD
Capecitabine—Cardiac disorder—Methotrexate—urinary bladder cancer	1.11e-05	0.000266	CcSEcCtD
Capecitabine—Urinary tract disorder—Epirubicin—urinary bladder cancer	1.1e-05	0.000265	CcSEcCtD
Capecitabine—Oedema peripheral—Epirubicin—urinary bladder cancer	1.1e-05	0.000265	CcSEcCtD
Capecitabine—Haematuria—Doxorubicin—urinary bladder cancer	1.1e-05	0.000264	CcSEcCtD
Capecitabine—Connective tissue disorder—Epirubicin—urinary bladder cancer	1.1e-05	0.000264	CcSEcCtD
Capecitabine—CDA—Metabolism—MTHFR—urinary bladder cancer	1.1e-05	0.000419	CbGpPWpGaD
Capecitabine—Urethral disorder—Epirubicin—urinary bladder cancer	1.09e-05	0.000263	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.09e-05	0.000416	CbGpPWpGaD
Capecitabine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	1.09e-05	0.000262	CcSEcCtD
Capecitabine—Epistaxis—Doxorubicin—urinary bladder cancer	1.08e-05	0.000261	CcSEcCtD
Capecitabine—Angiopathy—Methotrexate—urinary bladder cancer	1.08e-05	0.00026	CcSEcCtD
Capecitabine—TYMP—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000412	CbGpPWpGaD
Capecitabine—Immune system disorder—Methotrexate—urinary bladder cancer	1.08e-05	0.000259	CcSEcCtD
Capecitabine—Dizziness—Fluorouracil—urinary bladder cancer	1.08e-05	0.000259	CcSEcCtD
Capecitabine—Visual impairment—Epirubicin—urinary bladder cancer	1.07e-05	0.000259	CcSEcCtD
Capecitabine—Mediastinal disorder—Methotrexate—urinary bladder cancer	1.07e-05	0.000259	CcSEcCtD
Capecitabine—Agranulocytosis—Doxorubicin—urinary bladder cancer	1.07e-05	0.000258	CcSEcCtD
Capecitabine—Chills—Methotrexate—urinary bladder cancer	1.07e-05	0.000258	CcSEcCtD
Capecitabine—Diarrhoea—Cisplatin—urinary bladder cancer	1.06e-05	0.000254	CcSEcCtD
Capecitabine—Erythema multiforme—Epirubicin—urinary bladder cancer	1.05e-05	0.000254	CcSEcCtD
Capecitabine—Alopecia—Methotrexate—urinary bladder cancer	1.05e-05	0.000254	CcSEcCtD
Capecitabine—Vomiting—Gemcitabine—urinary bladder cancer	1.05e-05	0.000253	CcSEcCtD
Capecitabine—Bradycardia—Doxorubicin—urinary bladder cancer	1.05e-05	0.000253	CcSEcCtD
Capecitabine—Mental disorder—Methotrexate—urinary bladder cancer	1.04e-05	0.000251	CcSEcCtD
Capecitabine—Rash—Gemcitabine—urinary bladder cancer	1.04e-05	0.000251	CcSEcCtD
Capecitabine—Dermatitis—Gemcitabine—urinary bladder cancer	1.04e-05	0.000251	CcSEcCtD
Capecitabine—Eye disorder—Epirubicin—urinary bladder cancer	1.04e-05	0.000251	CcSEcCtD
Capecitabine—Hypersensitivity—Etoposide—urinary bladder cancer	1.04e-05	0.000251	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	1.04e-05	0.000398	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TERT—urinary bladder cancer	1.04e-05	0.000397	CbGpPWpGaD
Capecitabine—Tinnitus—Epirubicin—urinary bladder cancer	1.04e-05	0.00025	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.04e-05	0.000396	CbGpPWpGaD
Capecitabine—Malnutrition—Methotrexate—urinary bladder cancer	1.04e-05	0.00025	CcSEcCtD
Capecitabine—Erythema—Methotrexate—urinary bladder cancer	1.04e-05	0.00025	CcSEcCtD
Capecitabine—Haemoglobin—Doxorubicin—urinary bladder cancer	1.04e-05	0.00025	CcSEcCtD
Capecitabine—Headache—Gemcitabine—urinary bladder cancer	1.04e-05	0.00025	CcSEcCtD
Capecitabine—Flushing—Epirubicin—urinary bladder cancer	1.03e-05	0.000249	CcSEcCtD
Capecitabine—Cardiac disorder—Epirubicin—urinary bladder cancer	1.03e-05	0.000249	CcSEcCtD
Capecitabine—Vomiting—Fluorouracil—urinary bladder cancer	1.03e-05	0.000249	CcSEcCtD
Capecitabine—Rhinitis—Doxorubicin—urinary bladder cancer	1.03e-05	0.000249	CcSEcCtD
Capecitabine—Haemorrhage—Doxorubicin—urinary bladder cancer	1.03e-05	0.000249	CcSEcCtD
Capecitabine—Hepatitis—Doxorubicin—urinary bladder cancer	1.03e-05	0.000249	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.03e-05	0.000393	CbGpPWpGaD
Capecitabine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	1.03e-05	0.000247	CcSEcCtD
Capecitabine—TYMS—Metabolism—NAT2—urinary bladder cancer	1.03e-05	0.000392	CbGpPWpGaD
Capecitabine—Rash—Fluorouracil—urinary bladder cancer	1.03e-05	0.000247	CcSEcCtD
Capecitabine—Dermatitis—Fluorouracil—urinary bladder cancer	1.03e-05	0.000247	CcSEcCtD
Capecitabine—Pharyngitis—Doxorubicin—urinary bladder cancer	1.02e-05	0.000247	CcSEcCtD
Capecitabine—Headache—Fluorouracil—urinary bladder cancer	1.02e-05	0.000246	CcSEcCtD
Capecitabine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	1.02e-05	0.000245	CcSEcCtD
Capecitabine—Oedema peripheral—Doxorubicin—urinary bladder cancer	1.02e-05	0.000245	CcSEcCtD
Capecitabine—Dysgeusia—Methotrexate—urinary bladder cancer	1.02e-05	0.000245	CcSEcCtD
Capecitabine—Asthenia—Etoposide—urinary bladder cancer	1.01e-05	0.000244	CcSEcCtD
Capecitabine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	1.01e-05	0.000244	CcSEcCtD
Capecitabine—Angiopathy—Epirubicin—urinary bladder cancer	1.01e-05	0.000244	CcSEcCtD
Capecitabine—Urethral disorder—Doxorubicin—urinary bladder cancer	1.01e-05	0.000244	CcSEcCtD
Capecitabine—Immune system disorder—Epirubicin—urinary bladder cancer	1.01e-05	0.000243	CcSEcCtD
Capecitabine—Mediastinal disorder—Epirubicin—urinary bladder cancer	1e-05	0.000242	CcSEcCtD
Capecitabine—Back pain—Methotrexate—urinary bladder cancer	1e-05	0.000242	CcSEcCtD
Capecitabine—TYMP—Metabolism—TYMS—urinary bladder cancer	1e-05	0.000383	CbGpPWpGaD
Capecitabine—Chills—Epirubicin—urinary bladder cancer	1e-05	0.000241	CcSEcCtD
Capecitabine—Pruritus—Etoposide—urinary bladder cancer	1e-05	0.000241	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	9.98e-06	0.000381	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—PPARG—urinary bladder cancer	9.96e-06	0.000381	CbGpPWpGaD
Capecitabine—Arrhythmia—Epirubicin—urinary bladder cancer	9.96e-06	0.00024	CcSEcCtD
Capecitabine—Visual impairment—Doxorubicin—urinary bladder cancer	9.94e-06	0.00024	CcSEcCtD
Capecitabine—TYMP—Metabolism—NCOR1—urinary bladder cancer	9.91e-06	0.000379	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—GSTM1—urinary bladder cancer	9.91e-06	0.000379	CbGpPWpGaD
Capecitabine—Alopecia—Epirubicin—urinary bladder cancer	9.85e-06	0.000237	CcSEcCtD
Capecitabine—Nausea—Gemcitabine—urinary bladder cancer	9.83e-06	0.000237	CcSEcCtD
Capecitabine—Vomiting—Cisplatin—urinary bladder cancer	9.81e-06	0.000236	CcSEcCtD
Capecitabine—Vision blurred—Methotrexate—urinary bladder cancer	9.77e-06	0.000235	CcSEcCtD
Capecitabine—Mental disorder—Epirubicin—urinary bladder cancer	9.77e-06	0.000235	CcSEcCtD
Capecitabine—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.75e-06	0.000235	CcSEcCtD
Capecitabine—Rash—Cisplatin—urinary bladder cancer	9.73e-06	0.000234	CcSEcCtD
Capecitabine—Dermatitis—Cisplatin—urinary bladder cancer	9.72e-06	0.000234	CcSEcCtD
Capecitabine—Erythema—Epirubicin—urinary bladder cancer	9.71e-06	0.000234	CcSEcCtD
Capecitabine—Malnutrition—Epirubicin—urinary bladder cancer	9.71e-06	0.000234	CcSEcCtD
Capecitabine—Diarrhoea—Etoposide—urinary bladder cancer	9.67e-06	0.000233	CcSEcCtD
Capecitabine—Nausea—Fluorouracil—urinary bladder cancer	9.67e-06	0.000233	CcSEcCtD
Capecitabine—Eye disorder—Doxorubicin—urinary bladder cancer	9.64e-06	0.000232	CcSEcCtD
Capecitabine—Ill-defined disorder—Methotrexate—urinary bladder cancer	9.62e-06	0.000232	CcSEcCtD
Capecitabine—Tinnitus—Doxorubicin—urinary bladder cancer	9.62e-06	0.000232	CcSEcCtD
Capecitabine—Anaemia—Methotrexate—urinary bladder cancer	9.59e-06	0.000231	CcSEcCtD
Capecitabine—Flushing—Doxorubicin—urinary bladder cancer	9.58e-06	0.000231	CcSEcCtD
Capecitabine—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.58e-06	0.000231	CcSEcCtD
Capecitabine—DPYD—Metabolism—CREBBP—urinary bladder cancer	9.57e-06	0.000366	CbGpPWpGaD
Capecitabine—Flatulence—Epirubicin—urinary bladder cancer	9.56e-06	0.00023	CcSEcCtD
Capecitabine—Dysgeusia—Epirubicin—urinary bladder cancer	9.51e-06	0.000229	CcSEcCtD
Capecitabine—TYMP—Metabolism—GPX1—urinary bladder cancer	9.49e-06	0.000363	CbGpPWpGaD
Capecitabine—Back pain—Epirubicin—urinary bladder cancer	9.39e-06	0.000226	CcSEcCtD
Capecitabine—Angiopathy—Doxorubicin—urinary bladder cancer	9.36e-06	0.000225	CcSEcCtD
Capecitabine—Malaise—Methotrexate—urinary bladder cancer	9.35e-06	0.000225	CcSEcCtD
Capecitabine—Dizziness—Etoposide—urinary bladder cancer	9.35e-06	0.000225	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—ATM—urinary bladder cancer	9.34e-06	0.000357	CbGpPWpGaD
Capecitabine—Muscle spasms—Epirubicin—urinary bladder cancer	9.33e-06	0.000225	CcSEcCtD
Capecitabine—Immune system disorder—Doxorubicin—urinary bladder cancer	9.32e-06	0.000224	CcSEcCtD
Capecitabine—Vertigo—Methotrexate—urinary bladder cancer	9.32e-06	0.000224	CcSEcCtD
Capecitabine—TYMP—Metabolism—ERCC2—urinary bladder cancer	9.31e-06	0.000356	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CDK4—urinary bladder cancer	9.31e-06	0.000356	CbGpPWpGaD
Capecitabine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.3e-06	0.000224	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	9.3e-06	0.000355	CbGpPWpGaD
Capecitabine—Leukopenia—Methotrexate—urinary bladder cancer	9.28e-06	0.000224	CcSEcCtD
Capecitabine—Chills—Doxorubicin—urinary bladder cancer	9.26e-06	0.000223	CcSEcCtD
Capecitabine—Arrhythmia—Doxorubicin—urinary bladder cancer	9.22e-06	0.000222	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.17e-06	0.00035	CbGpPWpGaD
Capecitabine—Nausea—Cisplatin—urinary bladder cancer	9.16e-06	0.000221	CcSEcCtD
Capecitabine—Vision blurred—Epirubicin—urinary bladder cancer	9.15e-06	0.00022	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	9.14e-06	0.000349	CbGpPWpGaD
Capecitabine—Alopecia—Doxorubicin—urinary bladder cancer	9.12e-06	0.00022	CcSEcCtD
Capecitabine—Cough—Methotrexate—urinary bladder cancer	9.05e-06	0.000218	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—RB1—urinary bladder cancer	9.05e-06	0.000346	CbGpPWpGaD
Capecitabine—Mental disorder—Doxorubicin—urinary bladder cancer	9.04e-06	0.000218	CcSEcCtD
Capecitabine—Ill-defined disorder—Epirubicin—urinary bladder cancer	9.01e-06	0.000217	CcSEcCtD
Capecitabine—Vomiting—Etoposide—urinary bladder cancer	8.99e-06	0.000216	CcSEcCtD
Capecitabine—Erythema—Doxorubicin—urinary bladder cancer	8.98e-06	0.000216	CcSEcCtD
Capecitabine—Malnutrition—Doxorubicin—urinary bladder cancer	8.98e-06	0.000216	CcSEcCtD
Capecitabine—Anaemia—Epirubicin—urinary bladder cancer	8.97e-06	0.000216	CcSEcCtD
Capecitabine—Rash—Etoposide—urinary bladder cancer	8.91e-06	0.000215	CcSEcCtD
Capecitabine—Dermatitis—Etoposide—urinary bladder cancer	8.9e-06	0.000214	CcSEcCtD
Capecitabine—CDA—Metabolism—PPARG—urinary bladder cancer	8.88e-06	0.000339	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—RRM2—urinary bladder cancer	8.86e-06	0.000339	CbGpPWpGaD
Capecitabine—Headache—Etoposide—urinary bladder cancer	8.85e-06	0.000213	CcSEcCtD
Capecitabine—Flatulence—Doxorubicin—urinary bladder cancer	8.85e-06	0.000213	CcSEcCtD
Capecitabine—Arthralgia—Methotrexate—urinary bladder cancer	8.83e-06	0.000213	CcSEcCtD
Capecitabine—Myalgia—Methotrexate—urinary bladder cancer	8.83e-06	0.000213	CcSEcCtD
Capecitabine—Chest pain—Methotrexate—urinary bladder cancer	8.83e-06	0.000213	CcSEcCtD
Capecitabine—Dysgeusia—Doxorubicin—urinary bladder cancer	8.8e-06	0.000212	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—TP53—urinary bladder cancer	8.78e-06	0.000335	CbGpPWpGaD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.77e-06	0.000211	CcSEcCtD
Capecitabine—TYMP—Metabolism—MTHFR—urinary bladder cancer	8.76e-06	0.000335	CbGpPWpGaD
Capecitabine—Malaise—Epirubicin—urinary bladder cancer	8.75e-06	0.000211	CcSEcCtD
Capecitabine—Discomfort—Methotrexate—urinary bladder cancer	8.72e-06	0.00021	CcSEcCtD
Capecitabine—Vertigo—Epirubicin—urinary bladder cancer	8.72e-06	0.00021	CcSEcCtD
Capecitabine—Syncope—Epirubicin—urinary bladder cancer	8.7e-06	0.00021	CcSEcCtD
Capecitabine—Leukopenia—Epirubicin—urinary bladder cancer	8.69e-06	0.000209	CcSEcCtD
Capecitabine—Back pain—Doxorubicin—urinary bladder cancer	8.69e-06	0.000209	CcSEcCtD
Capecitabine—Muscle spasms—Doxorubicin—urinary bladder cancer	8.63e-06	0.000208	CcSEcCtD
Capecitabine—Palpitations—Epirubicin—urinary bladder cancer	8.58e-06	0.000207	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	8.54e-06	0.000326	CbGpPWpGaD
Capecitabine—Confusional state—Methotrexate—urinary bladder cancer	8.54e-06	0.000206	CcSEcCtD
Capecitabine—CDA—Metabolism—CREBBP—urinary bladder cancer	8.53e-06	0.000326	CbGpPWpGaD
Capecitabine—Loss of consciousness—Epirubicin—urinary bladder cancer	8.53e-06	0.000206	CcSEcCtD
Capecitabine—Cough—Epirubicin—urinary bladder cancer	8.47e-06	0.000204	CcSEcCtD
Capecitabine—Vision blurred—Doxorubicin—urinary bladder cancer	8.46e-06	0.000204	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.43e-06	0.000322	CbGpPWpGaD
Capecitabine—Infection—Methotrexate—urinary bladder cancer	8.41e-06	0.000203	CcSEcCtD
Capecitabine—Nausea—Etoposide—urinary bladder cancer	8.39e-06	0.000202	CcSEcCtD
Capecitabine—Hypertension—Epirubicin—urinary bladder cancer	8.38e-06	0.000202	CcSEcCtD
Capecitabine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	8.33e-06	0.000201	CcSEcCtD
Capecitabine—Nervous system disorder—Methotrexate—urinary bladder cancer	8.3e-06	0.0002	CcSEcCtD
Capecitabine—Anaemia—Doxorubicin—urinary bladder cancer	8.3e-06	0.0002	CcSEcCtD
Capecitabine—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.29e-06	0.0002	CcSEcCtD
Capecitabine—Myalgia—Epirubicin—urinary bladder cancer	8.26e-06	0.000199	CcSEcCtD
Capecitabine—Chest pain—Epirubicin—urinary bladder cancer	8.26e-06	0.000199	CcSEcCtD
Capecitabine—Arthralgia—Epirubicin—urinary bladder cancer	8.26e-06	0.000199	CcSEcCtD
Capecitabine—Anxiety—Epirubicin—urinary bladder cancer	8.24e-06	0.000198	CcSEcCtD
Capecitabine—Skin disorder—Methotrexate—urinary bladder cancer	8.22e-06	0.000198	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.21e-06	0.000198	CcSEcCtD
Capecitabine—TYMS—Metabolism—ENO2—urinary bladder cancer	8.2e-06	0.000314	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—HPGDS—urinary bladder cancer	8.2e-06	0.000314	CbGpPWpGaD
Capecitabine—Hyperhidrosis—Methotrexate—urinary bladder cancer	8.18e-06	0.000197	CcSEcCtD
Capecitabine—Discomfort—Epirubicin—urinary bladder cancer	8.16e-06	0.000197	CcSEcCtD
Capecitabine—Malaise—Doxorubicin—urinary bladder cancer	8.1e-06	0.000195	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—RB1—urinary bladder cancer	8.09e-06	0.000309	CbGpPWpGaD
Capecitabine—Dry mouth—Epirubicin—urinary bladder cancer	8.08e-06	0.000195	CcSEcCtD
Capecitabine—Vertigo—Doxorubicin—urinary bladder cancer	8.07e-06	0.000194	CcSEcCtD
Capecitabine—Anorexia—Methotrexate—urinary bladder cancer	8.07e-06	0.000194	CcSEcCtD
Capecitabine—Syncope—Doxorubicin—urinary bladder cancer	8.05e-06	0.000194	CcSEcCtD
Capecitabine—Leukopenia—Doxorubicin—urinary bladder cancer	8.04e-06	0.000194	CcSEcCtD
Capecitabine—Confusional state—Epirubicin—urinary bladder cancer	7.99e-06	0.000192	CcSEcCtD
Capecitabine—TYMS—Metabolism—GSTT1—urinary bladder cancer	7.96e-06	0.000304	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	7.95e-06	0.000304	CbGpPWpGaD
Capecitabine—Palpitations—Doxorubicin—urinary bladder cancer	7.94e-06	0.000191	CcSEcCtD
Capecitabine—Oedema—Epirubicin—urinary bladder cancer	7.92e-06	0.000191	CcSEcCtD
Capecitabine—Hypotension—Methotrexate—urinary bladder cancer	7.91e-06	0.000191	CcSEcCtD
Capecitabine—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.89e-06	0.00019	CcSEcCtD
Capecitabine—Infection—Epirubicin—urinary bladder cancer	7.87e-06	0.00019	CcSEcCtD
Capecitabine—DPYD—Metabolism—PTGS2—urinary bladder cancer	7.84e-06	0.0003	CbGpPWpGaD
Capecitabine—Cough—Doxorubicin—urinary bladder cancer	7.84e-06	0.000189	CcSEcCtD
Capecitabine—Shock—Epirubicin—urinary bladder cancer	7.79e-06	0.000188	CcSEcCtD
Capecitabine—Nervous system disorder—Epirubicin—urinary bladder cancer	7.77e-06	0.000187	CcSEcCtD
Capecitabine—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.76e-06	0.000187	CcSEcCtD
Capecitabine—Hypertension—Doxorubicin—urinary bladder cancer	7.75e-06	0.000187	CcSEcCtD
Capecitabine—Tachycardia—Epirubicin—urinary bladder cancer	7.73e-06	0.000186	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.71e-06	0.000186	CcSEcCtD
Capecitabine—Skin disorder—Epirubicin—urinary bladder cancer	7.69e-06	0.000185	CcSEcCtD
Capecitabine—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.66e-06	0.000184	CcSEcCtD
Capecitabine—Insomnia—Methotrexate—urinary bladder cancer	7.66e-06	0.000184	CcSEcCtD
Capecitabine—Arthralgia—Doxorubicin—urinary bladder cancer	7.65e-06	0.000184	CcSEcCtD
Capecitabine—Myalgia—Doxorubicin—urinary bladder cancer	7.65e-06	0.000184	CcSEcCtD
Capecitabine—Chest pain—Doxorubicin—urinary bladder cancer	7.65e-06	0.000184	CcSEcCtD
Capecitabine—Anxiety—Doxorubicin—urinary bladder cancer	7.62e-06	0.000184	CcSEcCtD
Capecitabine—Paraesthesia—Methotrexate—urinary bladder cancer	7.6e-06	0.000183	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.59e-06	0.000183	CcSEcCtD
Capecitabine—Discomfort—Doxorubicin—urinary bladder cancer	7.55e-06	0.000182	CcSEcCtD
Capecitabine—Anorexia—Epirubicin—urinary bladder cancer	7.55e-06	0.000182	CcSEcCtD
Capecitabine—Dyspnoea—Methotrexate—urinary bladder cancer	7.55e-06	0.000182	CcSEcCtD
Capecitabine—Dry mouth—Doxorubicin—urinary bladder cancer	7.48e-06	0.00018	CcSEcCtD
Capecitabine—Dyspepsia—Methotrexate—urinary bladder cancer	7.45e-06	0.00018	CcSEcCtD
Capecitabine—Hypotension—Epirubicin—urinary bladder cancer	7.4e-06	0.000178	CcSEcCtD
Capecitabine—Confusional state—Doxorubicin—urinary bladder cancer	7.39e-06	0.000178	CcSEcCtD
Capecitabine—Decreased appetite—Methotrexate—urinary bladder cancer	7.36e-06	0.000177	CcSEcCtD
Capecitabine—Oedema—Doxorubicin—urinary bladder cancer	7.33e-06	0.000177	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.31e-06	0.000176	CcSEcCtD
Capecitabine—Fatigue—Methotrexate—urinary bladder cancer	7.3e-06	0.000176	CcSEcCtD
Capecitabine—Infection—Doxorubicin—urinary bladder cancer	7.28e-06	0.000175	CcSEcCtD
Capecitabine—Pain—Methotrexate—urinary bladder cancer	7.24e-06	0.000174	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	7.22e-06	0.000174	CcSEcCtD
Capecitabine—Shock—Doxorubicin—urinary bladder cancer	7.21e-06	0.000174	CcSEcCtD
Capecitabine—Nervous system disorder—Doxorubicin—urinary bladder cancer	7.19e-06	0.000173	CcSEcCtD
Capecitabine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.18e-06	0.000173	CcSEcCtD
Capecitabine—Insomnia—Epirubicin—urinary bladder cancer	7.16e-06	0.000173	CcSEcCtD
Capecitabine—Tachycardia—Doxorubicin—urinary bladder cancer	7.15e-06	0.000172	CcSEcCtD
Capecitabine—Skin disorder—Doxorubicin—urinary bladder cancer	7.12e-06	0.000172	CcSEcCtD
Capecitabine—Paraesthesia—Epirubicin—urinary bladder cancer	7.11e-06	0.000171	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CDKN2A—urinary bladder cancer	7.11e-06	0.000272	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PPARG—urinary bladder cancer	7.1e-06	0.000271	CbGpPWpGaD
Capecitabine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7.09e-06	0.000171	CcSEcCtD
Capecitabine—Dyspnoea—Epirubicin—urinary bladder cancer	7.06e-06	0.00017	CcSEcCtD
Capecitabine—Anorexia—Doxorubicin—urinary bladder cancer	6.99e-06	0.000168	CcSEcCtD
Capecitabine—CDA—Metabolism—PTGS2—urinary bladder cancer	6.99e-06	0.000267	CbGpPWpGaD
Capecitabine—Feeling abnormal—Methotrexate—urinary bladder cancer	6.98e-06	0.000168	CcSEcCtD
Capecitabine—Dyspepsia—Epirubicin—urinary bladder cancer	6.97e-06	0.000168	CcSEcCtD
Capecitabine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.92e-06	0.000167	CcSEcCtD
Capecitabine—Decreased appetite—Epirubicin—urinary bladder cancer	6.89e-06	0.000166	CcSEcCtD
Capecitabine—Hypotension—Doxorubicin—urinary bladder cancer	6.85e-06	0.000165	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.84e-06	0.000165	CcSEcCtD
Capecitabine—DPYD—Metabolism—PTEN—urinary bladder cancer	6.84e-06	0.000261	CbGpPWpGaD
Capecitabine—Fatigue—Epirubicin—urinary bladder cancer	6.83e-06	0.000165	CcSEcCtD
Capecitabine—TYMP—Metabolism—CREBBP—urinary bladder cancer	6.82e-06	0.000261	CbGpPWpGaD
Capecitabine—Constipation—Epirubicin—urinary bladder cancer	6.77e-06	0.000163	CcSEcCtD
Capecitabine—Pain—Epirubicin—urinary bladder cancer	6.77e-06	0.000163	CcSEcCtD
Capecitabine—Urticaria—Methotrexate—urinary bladder cancer	6.72e-06	0.000162	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	6.72e-06	0.000257	CbGpPWpGaD
Capecitabine—Body temperature increased—Methotrexate—urinary bladder cancer	6.69e-06	0.000161	CcSEcCtD
Capecitabine—Abdominal pain—Methotrexate—urinary bladder cancer	6.69e-06	0.000161	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.68e-06	0.000161	CcSEcCtD
Capecitabine—Insomnia—Doxorubicin—urinary bladder cancer	6.63e-06	0.00016	CcSEcCtD
Capecitabine—TYMS—Metabolism—NQO1—urinary bladder cancer	6.61e-06	0.000253	CbGpPWpGaD
Capecitabine—Paraesthesia—Doxorubicin—urinary bladder cancer	6.58e-06	0.000159	CcSEcCtD
Capecitabine—Dyspnoea—Doxorubicin—urinary bladder cancer	6.53e-06	0.000157	CcSEcCtD
Capecitabine—Feeling abnormal—Epirubicin—urinary bladder cancer	6.53e-06	0.000157	CcSEcCtD
Capecitabine—DPYD—Metabolism—EP300—urinary bladder cancer	6.52e-06	0.000249	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	6.5e-06	0.000248	CbGpPWpGaD
Capecitabine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.48e-06	0.000156	CcSEcCtD
Capecitabine—Dyspepsia—Doxorubicin—urinary bladder cancer	6.45e-06	0.000155	CcSEcCtD
Capecitabine—Decreased appetite—Doxorubicin—urinary bladder cancer	6.37e-06	0.000153	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.33e-06	0.000152	CcSEcCtD
Capecitabine—Fatigue—Doxorubicin—urinary bladder cancer	6.32e-06	0.000152	CcSEcCtD
Capecitabine—Urticaria—Epirubicin—urinary bladder cancer	6.29e-06	0.000152	CcSEcCtD
Capecitabine—Constipation—Doxorubicin—urinary bladder cancer	6.27e-06	0.000151	CcSEcCtD
Capecitabine—Pain—Doxorubicin—urinary bladder cancer	6.27e-06	0.000151	CcSEcCtD
Capecitabine—Body temperature increased—Epirubicin—urinary bladder cancer	6.26e-06	0.000151	CcSEcCtD
Capecitabine—Abdominal pain—Epirubicin—urinary bladder cancer	6.26e-06	0.000151	CcSEcCtD
Capecitabine—Hypersensitivity—Methotrexate—urinary bladder cancer	6.24e-06	0.00015	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—EP300—urinary bladder cancer	6.19e-06	0.000236	CbGpPWpGaD
Capecitabine—CDA—Metabolism—PTEN—urinary bladder cancer	6.09e-06	0.000233	CbGpPWpGaD
Capecitabine—Asthenia—Methotrexate—urinary bladder cancer	6.07e-06	0.000146	CcSEcCtD
Capecitabine—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.04e-06	0.000146	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CCND1—urinary bladder cancer	6.01e-06	0.00023	CbGpPWpGaD
Capecitabine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.99e-06	0.000144	CcSEcCtD
Capecitabine—Pruritus—Methotrexate—urinary bladder cancer	5.99e-06	0.000144	CcSEcCtD
Capecitabine—Hypersensitivity—Epirubicin—urinary bladder cancer	5.84e-06	0.000141	CcSEcCtD
Capecitabine—Urticaria—Doxorubicin—urinary bladder cancer	5.82e-06	0.00014	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CDKN1A—urinary bladder cancer	5.81e-06	0.000222	CbGpPWpGaD
Capecitabine—CDA—Metabolism—EP300—urinary bladder cancer	5.81e-06	0.000222	CbGpPWpGaD
Capecitabine—Abdominal pain—Doxorubicin—urinary bladder cancer	5.79e-06	0.00014	CcSEcCtD
Capecitabine—Body temperature increased—Doxorubicin—urinary bladder cancer	5.79e-06	0.00014	CcSEcCtD
Capecitabine—Diarrhoea—Methotrexate—urinary bladder cancer	5.79e-06	0.00014	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.69e-06	0.000218	CbGpPWpGaD
Capecitabine—Asthenia—Epirubicin—urinary bladder cancer	5.68e-06	0.000137	CcSEcCtD
Capecitabine—Pruritus—Epirubicin—urinary bladder cancer	5.6e-06	0.000135	CcSEcCtD
Capecitabine—Dizziness—Methotrexate—urinary bladder cancer	5.6e-06	0.000135	CcSEcCtD
Capecitabine—TYMP—Metabolism—PTGS2—urinary bladder cancer	5.59e-06	0.000213	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—EP300—urinary bladder cancer	5.53e-06	0.000211	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTP1—urinary bladder cancer	5.52e-06	0.000211	CbGpPWpGaD
Capecitabine—Diarrhoea—Epirubicin—urinary bladder cancer	5.42e-06	0.000131	CcSEcCtD
Capecitabine—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.4e-06	0.00013	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.4e-06	0.000206	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.4e-06	0.000206	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—MYC—urinary bladder cancer	5.39e-06	0.000206	CbGpPWpGaD
Capecitabine—Vomiting—Methotrexate—urinary bladder cancer	5.38e-06	0.00013	CcSEcCtD
Capecitabine—Rash—Methotrexate—urinary bladder cancer	5.34e-06	0.000129	CcSEcCtD
Capecitabine—Dermatitis—Methotrexate—urinary bladder cancer	5.33e-06	0.000128	CcSEcCtD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.31e-06	0.000203	CbGpPWpGaD
Capecitabine—Headache—Methotrexate—urinary bladder cancer	5.3e-06	0.000128	CcSEcCtD
Capecitabine—Asthenia—Doxorubicin—urinary bladder cancer	5.26e-06	0.000127	CcSEcCtD
Capecitabine—Dizziness—Epirubicin—urinary bladder cancer	5.24e-06	0.000126	CcSEcCtD
Capecitabine—Pruritus—Doxorubicin—urinary bladder cancer	5.19e-06	0.000125	CcSEcCtD
Capecitabine—TYMS—Metabolism—GSTM1—urinary bladder cancer	5.07e-06	0.000194	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NCOR1—urinary bladder cancer	5.07e-06	0.000194	CbGpPWpGaD
Capecitabine—Vomiting—Epirubicin—urinary bladder cancer	5.04e-06	0.000121	CcSEcCtD
Capecitabine—Nausea—Methotrexate—urinary bladder cancer	5.03e-06	0.000121	CcSEcCtD
Capecitabine—Diarrhoea—Doxorubicin—urinary bladder cancer	5.02e-06	0.000121	CcSEcCtD
Capecitabine—Rash—Epirubicin—urinary bladder cancer	4.99e-06	0.00012	CcSEcCtD
Capecitabine—Dermatitis—Epirubicin—urinary bladder cancer	4.99e-06	0.00012	CcSEcCtD
Capecitabine—Headache—Epirubicin—urinary bladder cancer	4.96e-06	0.00012	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	4.94e-06	0.000189	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—PTEN—urinary bladder cancer	4.87e-06	0.000186	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GPX1—urinary bladder cancer	4.85e-06	0.000185	CbGpPWpGaD
Capecitabine—Dizziness—Doxorubicin—urinary bladder cancer	4.85e-06	0.000117	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—MYC—urinary bladder cancer	4.82e-06	0.000184	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—ERCC2—urinary bladder cancer	4.77e-06	0.000182	CbGpPWpGaD
Capecitabine—Nausea—Epirubicin—urinary bladder cancer	4.71e-06	0.000113	CcSEcCtD
Capecitabine—Vomiting—Doxorubicin—urinary bladder cancer	4.66e-06	0.000112	CcSEcCtD
Capecitabine—TYMP—Metabolism—EP300—urinary bladder cancer	4.65e-06	0.000178	CbGpPWpGaD
Capecitabine—Rash—Doxorubicin—urinary bladder cancer	4.62e-06	0.000111	CcSEcCtD
Capecitabine—Dermatitis—Doxorubicin—urinary bladder cancer	4.62e-06	0.000111	CcSEcCtD
Capecitabine—Headache—Doxorubicin—urinary bladder cancer	4.59e-06	0.000111	CcSEcCtD
Capecitabine—TYMS—Metabolism—MTHFR—urinary bladder cancer	4.48e-06	0.000171	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.45e-06	0.00017	CbGpPWpGaD
Capecitabine—Nausea—Doxorubicin—urinary bladder cancer	4.35e-06	0.000105	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.2e-06	0.00016	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.09e-06	0.000156	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TP53—urinary bladder cancer	3.96e-06	0.000151	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PPARG—urinary bladder cancer	3.63e-06	0.000139	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—CREBBP—urinary bladder cancer	3.49e-06	0.000133	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.28e-06	0.000125	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.27e-06	0.000125	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.14e-06	0.00012	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.96e-06	0.000113	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS2—urinary bladder cancer	2.86e-06	0.000109	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.55e-06	9.76e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTEN—urinary bladder cancer	2.49e-06	9.52e-05	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—EP300—urinary bladder cancer	2.38e-06	9.08e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.36e-06	9.04e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.36e-06	9.04e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.35e-06	8.98e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.29e-06	8.77e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.26e-06	8.63e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.91e-06	7.28e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.85e-06	7.07e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.61e-06	6.16e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.59e-06	6.08e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.54e-06	5.88e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.48e-06	5.65e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.46e-06	5.58e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.46e-06	5.58e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.4e-06	5.35e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.37e-06	5.25e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.29e-06	4.93e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.05e-06	4e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.01e-06	3.84e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.24e-07	3.15e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.18e-07	2.74e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—EP300—urinary bladder cancer	6.85e-07	2.62e-05	CbGpPWpGaD
